Patient characteristics
| Characteristic . | . |
|---|---|
| No. of patients | 121 |
| Age at HCT, y, n (%) | |
| Median (min-max) | 54 (18-74) |
| 18-29 | 20 (17) |
| 30-39 | 13 (11) |
| 40-49 | 16 (13) |
| 50-59 | 30 (25) |
| 60-69 | 37 (31) |
| ≥70 | 5 (4) |
| Recipient sex, n (%) | |
| Male | 70 (58) |
| Female | 51 (42) |
| Race, n (%) | |
| White | 110 (91) |
| Black or African American | 8 (7) |
| Asian | 3 (2) |
| Performance score at HCT, n (%) | |
| ≥90 | 77 (64) |
| <90 | 44 (36) |
| Indication for transplant, n (%) | |
| Malignant | |
| Acute Myeloid leukemia | 42 (35) |
| Acute lymphoblastic leukemia | 10 (8) |
| Other leukemia | 8 (7) |
| Chronic myeloid leukemia | 12 (10) |
| Myelodysplastic syndrome | 18 (15) |
| Other acute leukemia | 3 (2) |
| Non-Hodgkin lymphoma | 12 (10) |
| Hodgkin disease | 4 (3) |
| Plasma cell disorder/Multiple myeloma | 3 (2) |
| Myeloproliferative neoplasm | 3 (2) |
| Nonmalignant | |
| Severe aplastic anemia | 3 (2) |
| SCID and other immune system disorders | 2 (2) |
| Histiocytic disorders | 1 (1) |
| Prior autologous HCT, n (%) | |
| No | 107 (88) |
| Yes | 14 (12) |
| Conditioning intensity, n (%) | |
| Myeloablative conditioning | 76 (63) |
| Reduced intensity conditioning | 42 (35) |
| Undecided at the time of data collection | 3 (2) |
| TBI use, n (%) | |
| No | 68 (56) |
| Yes | 53 (44) |
| Marital status, n (%) | |
| Married or living with partner | 85 (70) |
| Single/separated/divorced/widowed | 28 (23) |
| Missing | 8 (7) |
| Work status, n (%) | |
| Full time | 60 (50) |
| Other | 49 (40) |
| Missing | 12 (10) |
| Household gross annual income, n (%) | |
| <$60 000 | 21 (17) |
| ≥$60 000 | 35 (29) |
| Declines/unknown | 65 (54) |
| Health insurance, n (%) | |
| Employer | 7 (6) |
| Medicaid | 12 (10) |
| Medicare | 12 (10) |
| Private | 64 (53) |
| Medicaid + private | 3 (2) |
| Medicare + private | 9 (7) |
| Self-pay | 1 (1) |
| Other | 8 (7) |
| Unknown | 5 (4) |
| Y of transplant, n (%) | |
| 2011 | 13 (11) |
| 2012 | 83 (69) |
| 2013 | 25 (21) |
| Follow-up in mo, median (range) | 73 (13-98) |
| Characteristic . | . |
|---|---|
| No. of patients | 121 |
| Age at HCT, y, n (%) | |
| Median (min-max) | 54 (18-74) |
| 18-29 | 20 (17) |
| 30-39 | 13 (11) |
| 40-49 | 16 (13) |
| 50-59 | 30 (25) |
| 60-69 | 37 (31) |
| ≥70 | 5 (4) |
| Recipient sex, n (%) | |
| Male | 70 (58) |
| Female | 51 (42) |
| Race, n (%) | |
| White | 110 (91) |
| Black or African American | 8 (7) |
| Asian | 3 (2) |
| Performance score at HCT, n (%) | |
| ≥90 | 77 (64) |
| <90 | 44 (36) |
| Indication for transplant, n (%) | |
| Malignant | |
| Acute Myeloid leukemia | 42 (35) |
| Acute lymphoblastic leukemia | 10 (8) |
| Other leukemia | 8 (7) |
| Chronic myeloid leukemia | 12 (10) |
| Myelodysplastic syndrome | 18 (15) |
| Other acute leukemia | 3 (2) |
| Non-Hodgkin lymphoma | 12 (10) |
| Hodgkin disease | 4 (3) |
| Plasma cell disorder/Multiple myeloma | 3 (2) |
| Myeloproliferative neoplasm | 3 (2) |
| Nonmalignant | |
| Severe aplastic anemia | 3 (2) |
| SCID and other immune system disorders | 2 (2) |
| Histiocytic disorders | 1 (1) |
| Prior autologous HCT, n (%) | |
| No | 107 (88) |
| Yes | 14 (12) |
| Conditioning intensity, n (%) | |
| Myeloablative conditioning | 76 (63) |
| Reduced intensity conditioning | 42 (35) |
| Undecided at the time of data collection | 3 (2) |
| TBI use, n (%) | |
| No | 68 (56) |
| Yes | 53 (44) |
| Marital status, n (%) | |
| Married or living with partner | 85 (70) |
| Single/separated/divorced/widowed | 28 (23) |
| Missing | 8 (7) |
| Work status, n (%) | |
| Full time | 60 (50) |
| Other | 49 (40) |
| Missing | 12 (10) |
| Household gross annual income, n (%) | |
| <$60 000 | 21 (17) |
| ≥$60 000 | 35 (29) |
| Declines/unknown | 65 (54) |
| Health insurance, n (%) | |
| Employer | 7 (6) |
| Medicaid | 12 (10) |
| Medicare | 12 (10) |
| Private | 64 (53) |
| Medicaid + private | 3 (2) |
| Medicare + private | 9 (7) |
| Self-pay | 1 (1) |
| Other | 8 (7) |
| Unknown | 5 (4) |
| Y of transplant, n (%) | |
| 2011 | 13 (11) |
| 2012 | 83 (69) |
| 2013 | 25 (21) |
| Follow-up in mo, median (range) | 73 (13-98) |
CMV, cytomegalovirus; GVHD, graft-versus-host disease; SCID, severe combined immunodeficiency; TBI, total body irradiation.